NDAORAL-28TABLET
Approved
Aug 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/50 28 is an oral contraceptive tablet containing mestranol and norethindrone, approved in 1968. It prevents pregnancy through hormonal suppression of ovulation and is taken as a 28-day cycle regimen. This product represents an earlier-generation combined oral contraceptive with relatively high estrogen content by modern standards.
LOE Approaching
This legacy oral contraceptive is approaching loss of exclusivity with moderate competitive pressure (30), signaling a contracting team and defensive commercial focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and LOE approaching, career opportunities on ORTHO-NOVUM 1/50 28 are minimal and focused on defensive, lower-visibility commercial roles. This product is unlikely to offer meaningful career advancement or visibility within Johnson & Johnson's portfolio.
Brand ManagerField Sales Representative
Worked on ORTHO-NOVUM 1/50 28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.